Isatuximab After Allogeneic Stem Cell Transplant
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 25 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Sanofi
- Tags
- Monoclonal Antibody, CD38, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1937
- NCT Identifier
- NCT05873205
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.